Last reviewed · How we verify

Propofol Abbott

El-Sahel Teaching Hospital · FDA-approved active Small molecule

Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system, leading to rapid onset of unconsciousness.

Propofol is a sedative-hypnotic agent that enhances inhibitory GABA neurotransmission in the central nervous system, leading to rapid onset of unconsciousness. Used for Induction and maintenance of general anesthesia, Sedation of intubated, mechanically ventilated patients in intensive care units.

At a glance

Generic namePropofol Abbott
Also known aspropofol
SponsorEl-Sahel Teaching Hospital
Drug classSedative-hypnotic agent; GABA-A receptor positive allosteric modulator
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia; Critical Care
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing the frequency and duration of chloride channel opening. This hyperpolarizes neuronal membranes and suppresses neuronal firing, resulting in sedation, hypnosis, and anesthesia. It has rapid onset and offset kinetics due to its lipophilic nature and rapid redistribution from the central nervous system.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: